• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: New data from CREDIBLE-CR with an updated meta-analysis.

作者信息

Gill Karan, Takamichi Baba, Cooper Andrew

机构信息

Shionogi B.V., London, United Kingdom.

Shionogi & Co., Ltd., Osaka, Japan.

出版信息

Int J Antimicrob Agents. 2024 Jun;63(6):107167. doi: 10.1016/j.ijantimicag.2024.107167. Epub 2024 Apr 4.

DOI:10.1016/j.ijantimicag.2024.107167
PMID:38582402
Abstract
摘要

相似文献

1
Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: New data from CREDIBLE-CR with an updated meta-analysis.基于头孢地尔的治疗方案对耐碳青霉烯鲍曼不动杆菌感染患者的临床疗效：来自CREDIBLE-CR的新数据及更新的荟萃分析
Int J Antimicrob Agents. 2024 Jun;63(6):107167. doi: 10.1016/j.ijantimicag.2024.107167. Epub 2024 Apr 4.
2
In reply to the Letter to the Editor regarding "Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis".针对致编辑的信，信的内容是关于“以头孢地尔为基础的治疗方案对耐碳青霉烯鲍曼不动杆菌感染患者的临床疗效：一项荟萃分析的系统评价”。
Int J Antimicrob Agents. 2024 Jun;63(6):107168. doi: 10.1016/j.ijantimicag.2024.107168. Epub 2024 Apr 4.
3
Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis.比较头孢地尔和多粘菌素为基础的方案治疗碳青霉烯类耐药鲍曼不动杆菌引起的严重感染：系统评价与荟萃分析和试验序贯分析。
BMC Infect Dis. 2024 Sep 13;24(1):967. doi: 10.1186/s12879-024-09899-5.
4
Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis.头孢地尔洛为基础的方案在治疗碳青霉烯类耐药鲍曼不动杆菌感染患者的临床疗效：系统评价与荟萃分析。
Int J Antimicrob Agents. 2024 Feb;63(2):107047. doi: 10.1016/j.ijantimicag.2023.107047. Epub 2023 Dec 5.
5
Should we, and how to, optimize cefiderocol administration during severe nosocomial pneumonia due to carbapenem-resistant Acinetobacter baumanii? A viewpoint.我们是否应该以及如何优化碳青霉烯类耐药鲍曼不动杆菌引起的严重医院获得性肺炎时的头孢地尔的给药方案？一种观点。
J Glob Antimicrob Resist. 2024 Sep;38:140-145. doi: 10.1016/j.jgar.2024.05.014. Epub 2024 Jun 5.
6
Heteroresistance to cefiderocol in carbapenem-resistant in the CREDIBLE-CR study was not linked to clinical outcomes: a analysis.可信碳青霉烯耐药研究中，对头孢地尔的异质性耐药与临床结局无关：一项 分析。
Microbiol Spectr. 2023 Dec 12;11(6):e0237123. doi: 10.1128/spectrum.02371-23. Epub 2023 Nov 15.
7
Successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis and purulent ventriculitis using cefiderocol combination therapy: a case report and literature review.使用头孢地尔联合疗法成功治疗耐碳青霉烯类鲍曼不动杆菌脑膜炎和化脓性脑室炎：病例报告及文献综述
Eur J Clin Microbiol Infect Dis. 2025 May;44(5):1245-1250. doi: 10.1007/s10096-025-05077-w. Epub 2025 Feb 21.
8
Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis With Sulbactam-Durlobactam.舒巴坦-多利培南成功治疗耐碳青霉烯鲍曼不动杆菌脑膜炎
Clin Infect Dis. 2024 Oct 15;79(4):819-825. doi: 10.1093/cid/ciae210.
9
Treatment-emergent cefiderocol resistance in carbapenem-resistant is associated with insertion sequence IS in the siderophore receptor .碳青霉烯类耐药 中治疗期出现的头孢他啶耐药与铁载体受体中的插入序列 IS 有关。
Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0029024. doi: 10.1128/aac.00290-24. Epub 2024 May 29.
10
Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence.头孢地尔在碳青霉烯类耐药鲍曼不动杆菌感染管理中的前瞻性作用：证据回顾。
Int J Antimicrob Agents. 2023 Aug;62(2):106882. doi: 10.1016/j.ijantimicag.2023.106882. Epub 2023 Jun 8.

引用本文的文献

1
treatment strategies: a review of therapeutic challenges and considerations.治疗策略：治疗挑战与考量综述
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0106324. doi: 10.1128/aac.01063-24. Epub 2025 Jul 9.
2
Are cefiderocol or sulbactam/durlobactam better than alternative best available treatment for infection by carbapenem-resistant A. baumannii? A systematic literature review.头孢地尔或舒巴坦/度洛巴坦在治疗耐碳青霉烯类鲍曼不动杆菌感染方面是否优于其他最佳可用治疗方法？一项系统文献综述。
Infection. 2025 Apr 7. doi: 10.1007/s15010-025-02527-7.
3
Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study.
头孢地尔在成年患者中的应用：一项前瞻性、多中心队列研究的描述性分析
Infect Dis Ther. 2024 Sep;13(9):1929-1948. doi: 10.1007/s40121-024-01016-y. Epub 2024 Jul 12.
4
Treatment Strategies of Colistin Resistance Infections.耐黏菌素感染的治疗策略
Antibiotics (Basel). 2024 May 6;13(5):423. doi: 10.3390/antibiotics13050423.